Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can steroids save lives during IPF Flare-Ups? new trial aims to find out

NCT ID NCT05674994

Recruiting now Disease control Sponsor: Fondation Hôpital Saint-Joseph Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether high-dose steroids (methylprednisolone and prednisone) can reduce deaths within 30 days for people hospitalized with a sudden worsening of idiopathic pulmonary fibrosis (IPF). About 110 adults with IPF and an acute exacerbation will receive either steroids or a placebo. Currently, no proven treatment exists for these dangerous episodes, which have a high short-term death rate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Methylprednisolone and Prednisone (corticosteroids)
What this could lead to
If successful, this could confirm that steroids improve survival during sudden worsening of IPF, offering a standard treatment for these dangerous flare-ups.
What could go wrong
This is a relatively small Phase 3 trial (110 people). Steroids may not improve survival and could have harmful side effects, as seen with other immunosuppressants in stable IPF.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

  • CHIC

    RECRUITING

    Créteil, France

  • CHRU Lille

    NOT_YET_RECRUITING

    Lille, France

  • CHU ANgers

    RECRUITING

    Angers, France

  • CHU BOrdeaux

    RECRUITING

    Bordeaux, France

  • CHU Caen

    RECRUITING

    Caen, France

  • CHU Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • CHU Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • CHU Nancy

    RECRUITING

    Nancy, France

  • CHU Nice

    NOT_YET_RECRUITING

    Nice, France

  • CHU Reims

    RECRUITING

    Reims, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Rouen

    NOT_YET_RECRUITING

    Rouen, France

  • CHU Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, France

  • CHU Toulouse

    RECRUITING

    Toulouse, France

  • CHU Tours

    NOT_YET_RECRUITING

    Tours, France

  • CHU de Besancon

    RECRUITING

    Besançon, France

  • CHU de Dijon

    RECRUITING

    Dijon, France

  • CHU de Montpellier

    NOT_YET_RECRUITING

    Montpellier, France

  • CHU de Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • Hospices Civils de Lyon

    RECRUITING

    Lyon, France

  • Hôpital Avicenne

    NOT_YET_RECRUITING

    Bobigny, France

  • Hôpital Bichat

    RECRUITING

    Paris, France

  • Hôpital Européen Georges Pompidou

    RECRUITING

    Paris, France

  • Hôpital FOCH

    NOT_YET_RECRUITING

    Paris, France

  • Hôpital Kremiln Bicetre

    RECRUITING

    Paris, France

  • Hôpital Nord

    RECRUITING

    Marseille, France

  • Hôpital Paris Saint-Joseph

    RECRUITING

    Paris, 75014, France

  • Hôpital Saint-Louis

    NOT_YET_RECRUITING

    Paris, France

  • Hôpital Tenon

    RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.